Travere Therapeutics (TVTX) – Research Analysts’ Recent Ratings Changes

Posted by on Jun 30th, 2026

Several brokerages have updated their recommendations and price targets on shares of Travere Therapeutics (NASDAQ: TVTX) in the last few weeks:

  • 6/25/2026 – Travere Therapeutics had its price target raised by Guggenheim from $56.00 to $65.00. They now have a “buy” rating on the stock.
  • 6/23/2026 – Travere Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
  • 6/22/2026 – Travere Therapeutics had its price target raised by Wedbush from $55.00 to $61.00. They now have an “outperform” rating on the stock.
  • 6/15/2026 – Travere Therapeutics had its price target raised by Citigroup Inc. from $62.00 to $70.00. They now have a “buy” rating on the stock.
  • 6/12/2026 – Travere Therapeutics had its price target raised by Wells Fargo & Company from $50.00 to $65.00. They now have an “overweight” rating on the stock.
  • 6/3/2026 – Travere Therapeutics had its price target raised by Citigroup Inc. from $59.00 to $62.00. They now have a “buy” rating on the stock.
  • 6/3/2026 – Travere Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $55.00 price target on the stock.
  • 6/2/2026 – Travere Therapeutics had its price target raised by HC Wainwright from $57.00 to $67.00. They now have a “buy” rating on the stock.
  • 5/21/2026 – Travere Therapeutics was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
  • 5/9/2026 – Travere Therapeutics was downgraded by Wall Street Zen from “buy” to “hold”.
  • 5/6/2026 – Travere Therapeutics was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
  • 5/6/2026 – Travere Therapeutics had its price target raised by Wells Fargo & Company from $40.00 to $50.00. They now have an “overweight” rating on the stock.
  • 5/5/2026 – Travere Therapeutics had its price target raised by Wedbush from $53.00 to $55.00. They now have an “outperform” rating on the stock.
  • 5/5/2026 – Travere Therapeutics had its price target raised by Citigroup Inc. from $53.00 to $59.00. They now have a “buy” rating on the stock.
  • 5/5/2026 – Travere Therapeutics had its price target raised by HC Wainwright from $47.00 to $57.00. They now have a “buy” rating on the stock.
  • 5/5/2026 – Travere Therapeutics had its price target raised by TD Cowen from $45.00 to $60.00. They now have a “buy” rating on the stock.

Insiders Place Their Bets

In other Travere Therapeutics news, insider Elizabeth E. Reed sold 2,076 shares of the business’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total value of $91,240.20. Following the transaction, the insider directly owned 105,211 shares of the company’s stock, valued at approximately $4,624,023.45. The trade was a 1.93% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider William E. Rote sold 2,763 shares of the firm’s stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $43.95, for a total transaction of $121,433.85. Following the sale, the insider directly owned 115,474 shares of the company’s stock, valued at approximately $5,075,082.30. This trade represents a 2.34% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 404,515 shares of company stock valued at $16,340,228 in the last 90 days. Company insiders own 4.44% of the company’s stock.

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

Featured Stories

Receive News & Ratings for Travere Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Travere Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.